SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-5076
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer ; volume:14 ; number:3 ; day:29 ; month:6 ; year:2021 ; pages:247-251 ; date:9.2021
Magazine of European Medical Oncology ; 14, Heft 3 (29.6.2021), 247-251, 9.2021
- Urheber
-
Bartsch, Rupert
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12254-021-00722-4
- URN
-
urn:nbn:de:101:1-2021112708364575831467
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bartsch, Rupert
- SpringerLink (Online service)
Ähnliche Objekte (12)
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Metastatic Triple-Negative Breast Cancer
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
How We Treat HER2-Positive Metastatic Breast Cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Metastatic Triple-Negative Breast Cancer
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
How We Treat HER2-Positive Metastatic Breast Cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Metastatic Triple-Negative Breast Cancer
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
How We Treat HER2-Positive Metastatic Breast Cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer